Australia markets closed

Edwards Lifesciences Corporation (E1WL34.SA)

São Paulo - São Paulo Delayed price. Currency in BRL
Add to watchlist
119.760.00 (0.00%)
At close: 04:14PM BRT
Full screen
Previous close119.76
Open0.00
Bid0.00 x N/A
Ask121.44 x N/A
Day's range0.00 - 0.00
52-week range
Volume0
Avg. volume12
Market cap290.331B
Beta (5Y monthly)1.11
PE ratio (TTM)9.49
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Five-Year Data Show Excellent Outcomes for Female and Small Annulus Patients With Edwards TAVR

    NEW YORK, June 05, 2024--Edwards Lifesciences (NYSE: EW) today announced the results from an analysis of data from the PARTNER Trials examining outcomes of transcatheter aortic valve replacement (TAVR) patients with a small annulus. Through five-year follow up of more than 1,300 low and intermediate risk SAPIEN 3 valve patients there were excellent clinical outcomes and valve durability irrespective of the patient’s annulus size or sex. These data were presented during the late-breaking clinical

  • PR Newswire

    BD to Acquire Edwards Lifesciences' Critical Care Product Group for $4.2 Billion to Expand Smart Connected Care Solutions and Become an Advanced Monitoring Technology Leader

    BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Edwards Lifesciences (NYSE: EW), today announced a definitive agreement under which BD will acquire Edwards' Critical Care product group ("Critical Care"), a global leader in advanced monitoring solutions, for $4.2 billion in cash, unlocking new value creation opportunities and enhancing BD's portfolio of smart connected care solutions.

  • Business Wire

    Edwards Lifesciences to Sell Critical Care to BD

    IRVINE, CA, June 03, 2024--Edwards Lifesciences (NYSE: EW) today announced it has entered into a definitive agreement to sell its Critical Care product group to BD (Becton, Dickinson and Company) (NYSE: BDX), in an all-cash transaction valued at $4.2 billion. With this agreement, Edwards is no longer pursuing the previously announced spin-off of Critical Care.